“Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Evaluation of Creatine Phosphokinase Elevations in the Phase 3 POETYK PSO-1 and PSO-2 Trials”. SKIN The Journal of Cutaneous Medicine 7, no. 6 (November 13, 2023): s244. Accessed May 22, 2026. https://skin.dermsquared.com/skin/article/view/2354.